ClinicalTrials.gg
CompletedNCT03880825Updated Aug 30, 2019

Drug Interaction Study of Levoketoconazole and Metformin

A Phase 1 interventional study of Metformin 500 mg Oral Tablet and Levoketoconazole 150 - 600 mg (BID) in Healthy Subjects, sponsored by Cortendo AB. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-08-30.

Sponsored by Cortendo AB · Phase 1, Interventional, and Other

From the registry’s dates

  • Primary completion was May 2019, 7 years 6 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
32
Allocation
Non-randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

This is a phase I, open-label, fixed-sequence drug-drug interaction study to evaluate the effect of levoketoconazole on the single-dose PK of metformin in health subjects.

Read the detailed description

This study will enroll healthy male and female subjects to evaluate the effect of levoketoconazole on the PK of a single 500 mg dose of metformin. There will be 3 sequential treatment periods, and all subjects will receive metformin only in Period 1, escalating doses of levoketoconazole in Period 2, and concurrent administration of metformin and levoketoconazole in Period 3.

02

Conditions studied

  • Healthy Subjects
03

In context

Lead sponsor

Cortendo AB is the lead sponsor of 6 studies on the registry; none are open to participants now.

Of its 6 completed or terminated interventional studies of FDA-regulated products, 3 (50%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. 18-55 years of age, inclusive, at time of consent.
  2. (BMI) between 18 and 32 kg/m2, inclusive.
  3. In good general physical health as determined by absence of medical history, physical examination findings, vital signs, clinical laboratory evaluations and measurements.
  4. Has not consumed and agrees to abstain from taking any prescription drugs, dietary supplements including vitamins and herbal preparations, or non-prescription drugs (except as authorized by the Investigator AND Medical Monitor) for 14 days prior to initial CRU admission on Day -1 and through Follow-Up.
  5. Has not consumed alcohol-containing beverages for 3 days prior to initial CRU admission on Day -1 and agrees not to consume alcohol for the duration of the study through Follow-Up.
  6. Is a nonsmoker (for at least 3 months) with negative urinary cotinine test at Screening and agrees to abstain from tobacco- and nicotine containing products for the duration of the study.

Exclusion criteria

Exclusion Criteria:

  1. Evidence of any out-of-normal-range laboratory value at Screening that has not been reviewed, approved, and documented as Not by the Investigator (except for LFTs, which must be within the normal range).
  2. Concurrent medical illness that would interfere with the conduct of the study in the opinion of the Investigator.
  3. History or presence of clinically significant cardiovascular, pulmonary, hematologic, endocrine, immunologic, dermatologic, neurologic, psychiatric, renal, hepatic, chronic respiratory, or gastrointestinal disease as judged by the Investigator.
  4. Clinically significant abnormality or confirmed interval > 450 msec at Screening or unconfirmed QTcF interval > 450 msec at CRU admission.
  5. Family history (parents, siblings, and offspring) of QT interval sudden cardiac death.
  6. Positive urine drug screen for drugs-of-abuse, including cocaine, 3,4 methylenedioxy-methamphetamine (MDMA), tetrahydrocannabinol, opioids, benzodiazepines, amphetamines, and barbiturates, and/or positive urine screen for alcohol at Screening and CRU admission.
  7. Positive urinary cotinine test at Screening.
  8. Treatment with an drug within the longer of 30 days or five half-lives of the investigational drug preceding the first dose of study drug.
  9. Positive for (HIV), , and/or on Screening assessments.
  10. Acute illness within 7 days of the first CRU admission on Day -1.
  11. Donated plasma within 7 days of Screening.
  12. Donated 1 or more pints of blood (or equivalent blood loss) within 30 days prior to Screening.
  13. History of caffeine consumption exceeding 8 cups of coffee/day (1 cup = 8 fluid ounces) within 14 days prior to first dose, or consumption of any caffeine- or chocolate-containing products for 3 days prior to CRU admission each week. Caffeine containing foods and/or beverages (e.g., tea and cola) should be considered equivalent to coffee.
  14. History of regular alcohol consumption exceeding 14 drinks/week (1 drink = 5 ounces of wine, 12 ounces of beer, or 1.5 ounces of hard liquor) within 180 days of Screening.
  15. Female subject who is pregnant or lactating.
  16. Male with less than 12.0 g/dL; Female with hemoglobin less than 11.0 g/dL.
  17. Had difficulties swallowing whole tablets.
  18. Body habitus prevents repeated venipuncture.
  19. History of or allergy to metformin.
  20. History of hypoglycemia.
  21. Participated in the COR-2017-02 levoketoconazole food effect study.
  22. History of drug-induced liver injury from any drug.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
32 participants (actual)

Study arms

  • Other
    Metformin Only

    Drug: Metformin 500 mg Oral Tablet

  • Other
    Levoketoconazole Only

    Drug: Levoketoconazole 150 - 600 mg (BID)

  • Other
    Levoketoconazole + Metformin

    Drug: Metformin 500 mg Oral Tablet · Drug: Levoketoconazole 150 - 600 mg (BID)

Interventions

  • single dose

  • DrugLevoketoconazole 150 - 600 mg (BID)

    escalating dose from 150 mg to 600 mg (BID)

    Also known as: COR-003

06

What researchers measure

Primary outcomes

  1. Maximum observed plasma concentration (Cmax) of metformin

    Maximum observed plasma concentration (Cmax) of metformin with and without concomitant administration of levoketoconazole.

    Time frame: 48 hours

  2. Time to maximum concentration (Tmax) of metformin

    Time to maximum concentration (Tmax) of metformin with and without concomitant administration of levoketoconazole.

    Time frame: 48 hours

  3. Area under the plasma concentration-time curve (AUC) of metformin

    Area under the plasma concentration-time curve (AUC) from time 0 to time of last measurable plasma concentration (AUClast) and from time 0 extrapolated to infinity (AUCinf) of metformin with and without concomitant administration of levoketoconazole.

    Time frame: 48 hours

Secondary outcomes

  1. Renal clearance (CLr) of metformin

    Renal clearance (CLr) of metformin with and without concomitant administration of levoketoconazole.

    Time frame: 24 hours

  2. Incidence of Adverse Events

    Incidence of Treatment-Emergent AEs (TEAEs), AESIs, and Serious Adverse Events (SAEs). Incidence of Treatment-Emergent AEs (TEAEs), AESIs, and Serious Adverse Events (SAEs).

    Time frame: 35 days

07

Study locations

1 site
  • Clinical Pharmacology of Miami, LLC
    Miami, Florida 33014, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2019 to primary completion in May 2019, 1 month.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 18, 2019
First posted
Mar 19, 2019
StartActual
Mar 28, 2019
Primary completionActual
May 3, 2019
CompletionActual
May 3, 2019
Last update
Aug 30, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 30, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03880825
Lead sponsor
Cortendo AB
Responsible party
Sponsor
First posted
Mar 19, 2019
Start date
Mar 28, 2019
Primary completion
May 3, 2019
Completion
May 3, 2019
Last update
Aug 30, 2019

Study contacts

Steven Schoenfeld, MD
study director · Cortendo AB

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Metformin

Start the discussion